Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABBV-951 Infusion in Parkinson's Disease
NCT03374917Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of foslevodopa and foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Infusion Site Reactions at 28 days, Number of Participants with Adverse Events up to 2 months and 4 more. Started Apr 2018; status: completed.
02
Drugs
foslevodopafoscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03374917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374917.